Cargando…

Early eculizumab use in atypical haemolytic uraemic syndrome in a Jehovah’s Witness refusing blood products

Thrombotic microangiopathy (TMA) is characterized by microscopic angiopathic haemolytic anaemia, thrombocytopenia and organ injury. Supportive therapies include the use of blood products. Recently the terminal complement inhibitor eculizumab has been approved in atypical haemolytic uraemic syndrome...

Descripción completa

Detalles Bibliográficos
Autores principales:	Al-Shaghana, May, Bentall, Andrew, Jesky, Mark D., Lester, William, Lipkin, Graham
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471596/ https://www.ncbi.nlm.nih.gov/pubmed/28638625 http://dx.doi.org/10.1093/omcr/omx025

Ejemplares similares

Eculizumab in secondary atypical haemolytic uraemic syndrome
por: Cavero, Teresa, et al.
Publicado: (2017)

Early treatment with eculizumab in atypical haemolytic uraemic syndrome
por: Garjau, Maria, et al.
Publicado: (2012)

Blood Transfusion in Children: The Refusal of Jehovah’s Witness Parents’
por: Conti, Adelaide, et al.
Publicado: (2018)

Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome
por: Macia, Manuel, et al.
Publicado: (2017)

Outcome of atypical haemolytic uraemic syndrome relapse after eculizumab withdrawal
por: Duineveld, Caroline, et al.
Publicado: (2020)

Eculizumab and drug-induced haemolytic–uraemic syndrome
por: Faguer, Stanislas, et al.
Publicado: (2013)

A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)
por: Rathbone, John, et al.
Publicado: (2013)

Rescue therapy with eculizumab in a transplant recipient with atypical haemolytic-uraemic syndrome
por: Durán, Carlos E., et al.
Publicado: (2012)

Eculizumab in atypical haemolytic–uraemic syndrome allows cessation of plasma exchange and dialysis
por: Kim, Jon Jin, et al.
Publicado: (2012)

Economic Impact of Early-in-Hospital Diagnosis and Initiation of Eculizumab in Atypical Haemolytic Uraemic Syndrome
por: Ryan, Michael, et al.
Publicado: (2019)

Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome
por: Walsh, Patrick R., et al.
Publicado: (2018)

Atypical Haemolytic Uraemic Syndrome Associated with Clostridium difficile Infection Successfully Treated with Eculizumab
por: Inglis, Joshua M., et al.
Publicado: (2018)

Eculizumab discontinuation in atypical haemolytic uraemic syndrome: TMA recurrence risk and renal outcomes
por: Ariceta, Gema, et al.
Publicado: (2021)

Progression to end-stage renal disease is reduced with eculizumab in patients with atypical haemolytic uraemic syndrome
por: Walle, J Vande, et al.
Publicado: (2015)

10. Is Eculizumab a life-saving treatment for atypical Haemolytic Uraemic Syndrome in Lupus Pregnancy?
por: McGrath, Catherine, et al.
Publicado: (2017)

Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10‐year pharmacovigilance analysis
por: Socié, Gérard, et al.
Publicado: (2019)

Eculizumab in a child with atypical haemolytic uraemic syndrome and haemophagocytic lymphohistiocytosis triggered by cytomegalovirus infection
por: Fraga-Rodriguez, Gloria M, et al.
Publicado: (2017)

Proposal for individualized dosing of eculizumab in atypical haemolytic uraemic syndrome: patient friendly and cost-effective
por: ter Avest, Mendy, et al.
Publicado: (2022)

Eculizumab treatment of atypical haemolytic uraemic syndrome: results from the largest prospective clinical trial to date
por: weekers, LE, et al.
Publicado: (2014)

Successful Subsequent Pregnancy in a Woman Receiving Eculizumab for Pregnancy-Associated Atypical Haemolytic Uraemic Syndrome
por: Bateman, Samantha, et al.
Publicado: (2019)

Post-partum atypical haemolytic-uraemic syndrome treated with eculizumab: terminal complement activity assessment in clinical practice
por: Delmas, Yahsou, et al.
Publicado: (2013)

Post-partum atypical haemolytic-uraemic syndrome treated with eculizumab: terminal complement activity assessment in clinical practice
por: Delmas, Yahsou, et al.
Publicado: (2013)

Eculizumab prevents thrombotic microangiopathy in patients with atypical haemolytic uraemic syndrome in a long-term observational study
por: Menne, Jan, et al.
Publicado: (2018)

Eculizumab for paediatric patients with atypical haemolytic uraemic syndrome: full dataset analysis of post-marketing surveillance in Japan
por: Ito, Shuichi, et al.
Publicado: (2022)

Successful treatment of a Streptococcus pneumoniae-associated haemolytic uraemic syndrome by eculizumab
por: Jeantet, Guillaume, et al.
Publicado: (2018)

Between Autonomy and Paternalism: Attitudes of Nursing Personnel Towards Jehovah’s Witnesses’ Refusal of Blood Transfusion
por: Domaradzki, Jan, et al.
Publicado: (2023)

Treatment of atypical uraemic syndrome in the era of eculizumab
por: Fremeaux-Bacchi, Veronique
Publicado: (2012)

Novel complement factor H gene mutation causing atypical haemolytic uraemic syndrome: early Eculizumab prevents acute dialysis
por: Collett, James, et al.
Publicado: (2017)

Ravulizumab: A Review in Atypical Haemolytic Uraemic Syndrome
por: Syed, Yahiya Y.
Publicado: (2021)

Early initiation of eculizumab treatment in patients with atypical haemolytic uraemic syndrome improves long-term outcomes: a pooled analysis of clinical trials
por: Walle, J Vande, et al.
Publicado: (2015)

Recent advances in diagnosis and treatment of atypical haemolytic uraemic syndrome
por: Bolton-Maggs, Paula HB
Publicado: (2010)

Complement therapy in atypical haemolytic uraemic syndrome (aHUS)
por: Wong, Edwin K.S., et al.
Publicado: (2013)

Correction to: Ravulizumab: A Review in Atypical Haemolytic Uraemic Syndrome
por: Syed, Yahiya Y.
Publicado: (2021)

Correction to: Ravulizumab: A Review in Atypical Haemolytic Uraemic Syndrome
por: Syed, Yahiya Y.
Publicado: (2021)

Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab
por: Delmas, Yahsou, et al.
Publicado: (2014)

Safety and impact of eculizumab withdrawal in patients with atypical haemolytic uraemic syndrome: protocol for a multicentre, open-label, prospective, single-arm study
por: Dunn, Sarah, et al.
Publicado: (2022)

Jehovah’s Witnesses and Their Compliance with Regulations on Smoking and Blood Treatment
por: Pavlikova, Barbara, et al.
Publicado: (2021)

Atypical Haemolytic Uraemic Syndrome Associated with a Hybrid Complement Gene
por: Venables, Julian P, et al.
Publicado: (2006)

AZD-1222: Atypical haemolytic uraemic syndrome recurrence: case report
Publicado: (2022)

Cisplatin-induced haemolytic uraemic syndrome associated with a novel intronic mutation of CD46 treated with eculizumab
por: Gilbert, Rodney D., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_pjppnopb5dhd67apg6rndo6fpn